NCT02805504

Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures

Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 136 (actual)
• Sponsor: Loma Linda University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.

Detailed description

A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries. Subjects of prospective study will be randomly divided using electronic program into two groups: The first group will receive intraoperative local Liposomal Bupivacaine injection at the port placement site. The control group will receive will local Marcaine (bupivacaine HCl) injection Primary Outcome Measures: * Total opioid consumption measured in intravenous morphine equivalents dose during the postoperative hospital Stay * Postoperative pain assessment using visual Analog Pain Scores \& Brief Pain Inventory form. * Length of Hospital Stay * Time to First Opioid Use. * Postoperative Constipation , paralytic ileus

Conditions

• Urinary Tract Diseases

Interventions

Type	Name	Description
DRUG	Exparel	This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.
DRUG	Marcaine	This group will receive intraoperative Bupivacaine HCl injection at the surgical site.

Timeline

• Start date: 2016-07-11
• Primary completion: 2022-05-09
• Completion: 2022-05-09
• First posted: 2016-06-20
• Last updated: 2024-04-24
• Results posted: 2024-04-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study